← Leaderboards
Janet T. Holbrook
Johns Hopkins University
$51,624,279
Attributed
$60,828,547
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.7M · FY2005–22$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$60,828,547 · 7
By mechanism
U10$41,975,496 · 2
U01$9,113,468 · 3
UG1$9,004,458 · 1
R34$735,125 · 1
Top collaborators
- Robert A. Wise11 shared
- Elizabeth Ann Sugar5 shared
- Michael Frank Busk3 shared
- Brendan J Canning3 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Douglas A Jabs$24,554,490
- Brendan J Canning$6,876,349
- Robert A. Wise$33,179,807
- Elizabeth Ann Sugar$11,501,247
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsClinical TrialsParticipantReportingAdrenal Cortex HormonesSafetyMonitorProtocols DocumentationInflammationDesignUveitisBaseImplantRandomizedTreatment TrialBlindnessFollow-UpPilot ProjectsPublicationsData QualityProceduresData CollectionAdverse EffectsOral
Grant awards (40)
ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial$972,337
UG1 · FY2022 · EY · contact PI
ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial$2,640,821
UG1 · FY2021 · EY · contact PI
ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial$2,717,020
UG1 · FY2020 · EY · contact PI
ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial$1,915,534
UG1 · FY2019 · EY · contact PI
Macular Edema Treatment Trials Associated with MUST (META-MUST)$948,462
U10 · FY2019 · EY · contact PI
Effect of Losartan on Progression of Emphysema$364,499
U01 · FY2019 · HL
Macular Edema Treatment Trials Associated with MUST (META-MUST)$1,684,753
U10 · FY2018 · EY · contact PI
ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial$758,746
UG1 · FY2018 · EY · contact PI
Effect of Losartan on Progression of Emphysema$364,500
U01 · FY2018 · HL
Pilot Study of Zinc Acetate for Chronic Cough$163,750
R34 · FY2018 · HL
Macular Edema Treatment Trials Associated with MUST (META-MUST)$1,922,926
U10 · FY2017 · EY · contact PI
Effect of Losartan on Progression of Emphysema$364,500
U01 · FY2017 · HL
Pilot Study of Zinc Acetate for Chronic Cough$286,125
R34 · FY2017 · HL
Macular Edema Treatment Trials Associated with MUST (META-MUST)$1,931,632
U10 · FY2016 · EY · contact PI
Competitive Renewal for Multicenter Uveitis Steroid Treatment (MUST) Trial$651,433
U10 · FY2016 · EY · contact PI
Effect of Losartan on Progression of Emphysema$364,500
U01 · FY2016 · HL
Pilot Study of Zinc Acetate for Chronic Cough$285,250
R34 · FY2016 · HL
Competitive Renewal for Multicenter Uveitis Steroid Treatment (MUST) Trial$1,535,936
U10 · FY2015 · EY · contact PI
Effect of Losartan on Progression of Emphysema$364,500
U01 · FY2015 · HL
Macular Edema Treatment Trials Associated with MUST (META-MUST)$183,715
U10 · FY2015 · EY · contact PI
Macular Edema Treatment Trials Associated with MUST (META-MUST)$9,924
U10 · FY2015 · EY · contact PI
Macular Edema Treatment Trials Associated with MUST (META-MUST)$1,653,414
U10 · FY2014 · EY · contact PI
Competitive Renewal for Multicenter Uveitis Steroid Treatment (MUST) Trial$1,535,936
U10 · FY2014 · EY · contact PI
Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients wit*$1,887,086
U01 · FY2013 · HL · contact PI
Competitive Renewal for Multicenter Uveitis Steroid Treatment (MUST) Trial$1,535,936
U10 · FY2013 · EY · contact PI
Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients wit*$1,955,869
U01 · FY2012 · HL · contact PI
Competitive Renewal for Multicenter Uveitis Steroid Treatment (MUST) Trial$1,508,636
U10 · FY2012 · EY · contact PI
Competitive Renewal for Multicenter Uveitis Steroid Treatment (MUST) Trial$42,800
U10 · FY2012 · EY · contact PI
Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients wit*$1,108,104
U01 · FY2011 · HL · contact PI
Study of Acid Reflux Therapy for Children with Asthma$466,849
U01 · FY2010 · HL · contact PI
Multi-Center Uveitis Steriod Treatment (MUST) Trial$6,249,789
U10 · FY2009 · EY · contact PI
Study of Acid Reflux Therapy for Children with Asthma$479,930
U01 · FY2009 · HL · contact PI
Multi-Center Uveitis Steriod Treatment (MUST) Trial$5,369,540
U10 · FY2008 · EY · contact PI
Study of Acid Reflux Therapy for Children with Asthma$457,744
U01 · FY2008 · HL · contact PI
Multi-Center Uveitis Steriod Treatment (MUST) Trial$5,057,448
U10 · FY2007 · EY · contact PI
Study of Acid Reflux Therapy for Children with Asthma$453,711
U01 · FY2007 · HL · contact PI
Multi-Center Uveitis Steriod Treatment (MUST) Trial$4,534,870
U10 · FY2006 · EY · contact PI
Study of Acid Reflux Therapy for Children with Asthma$481,676
U01 · FY2006 · HL · contact PI
Multi-Center Uveitis Steriod Treatment (MUST) Trial$1,793,111
U10 · FY2005 · EY
Multi-Center Uveitis Steriod Treatment (MUST) Trial$3,825,235
U10 · FY2004 · EY